Onyx Biotec Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Onyx Biotec Ltd Q2 FY27 key numbers
- Revenue
- Revenue from operations for the quarter ended September 30, 2026: ₹4,340.86 Lakhs.
As stated in Onyx Biotec Ltd's Q2 FY27 results statement · published 15 Nov 2026. Reported figures, not investment advice.
Based on Onyx Biotec Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the quarter ended September 30, 2026: ₹4,340.86 Lakhs. EBITDA for the quarter ended Sep 30, 2026: ₹270.59 lakhs (Calculated as Profit before exceptional items and tax ₹125.83 lakhs + Depreciation ₹144.54 lakhs).
From Onyx Biotec Ltd's Q2 FY27 earnings-call transcript · updated 15 Nov 2026.
How did Onyx Biotec's revenue grow in the September 2026 quarter?
- Revenue from operations for the quarter ended September 30, 2026: ₹4,340.86 Lakhs
- Revenue from operations for the same quarter previous year (September 30, 2025): ₹3,458.50 Lakhs
- Year-on-year revenue growth: ₹4,340.86 Lakhs vs ₹3,458.50 Lakhs, an increase of approximately 25.47%
2 more points from Onyx Biotec Ltd's call on revenue
Create a free account to keep reading this call
What happened to Onyx Biotec's margins in Q2 FY27?
See what Onyx Biotec Ltd said on profitability & margins — free account, 30 seconds.
What capex is Onyx Biotec planning?
- Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use
- Allocation: INR 607.70 Lakhs (original), Fund utilized: INR 573.30 Lakhs
- Status: Nil deviation, advance of INR 22.07 Lakhs paid as of September 30, 2026; bills to be received post-completion
- Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections
- Allocation: INR 124.05 Lakhs (original), Fund utilized: INR 91.55 Lakhs
- Work in progress
2 more points from Onyx Biotec Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Onyx Biotec raising money or cutting debt?
See what Onyx Biotec Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Onyx Biotec's order book?
See what Onyx Biotec Ltd said on order book & pipeline — free account, 30 seconds.
More Q2 FY27 results in Pharmaceuticals & Biotechnology
- Sun Pharmaceutical Industries Q2 FY27 results
- Divis Laboratories Q2 FY27 resultsCapex ₹1,638 Cr
- Torrent Pharmaceuticals Q2 FY27 results
- Laurus Labs Q2 FY27 results
- Zydus Lifesciences Q2 FY27 results
- Dr Reddy's Labs Q2 FY27 resultsCapex ₹186 Cr
- Cipla Q2 FY27 results
- Mankind Pharma Q2 FY27 results
All Q2 FY27 results | Pharmaceuticals & Biotechnology rankings
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Onyx Biotec Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Onyx Biotec Ltd Q2 FY27 results?
Revenue from operations for the quarter ended September 30, 2026: ₹4,340.86 Lakhs. EBITDA for the quarter ended Sep 30, 2026: ₹270.59 lakhs (Calculated as Profit before exceptional items and tax ₹125.83 lakhs + Depreciation ₹144.54 lakhs).
What is Onyx Biotec Ltd share price analysis?
Onyx Biotec Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹71 Cr. Investors should review the full earnings analysis for detailed insights.
Is Onyx Biotec Ltd planning capital expenditure?
Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use.
Keep Onyx Biotec Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
